Suppr超能文献

用CaNa2EDTA改善111铟和90钇-DTPA-抗癌胚抗原单克隆抗体在荷人结肠癌裸鼠中的放射免疫检测和放射免疫治疗。

CaNa2EDTA for improvement of radioimmunodetection and radioimmunotherapy with 111In and 90Y-DTPA-anti-CEA MAbs in nude mice bearing human colorectal cancer.

作者信息

Watanabe N, Oriuchi N, Endo K, Inoue T, Kuroki M, Matsuoka Y, Tanada S, Murata H, Kim E E, Sasaki Y

机构信息

Division of Advanced Technology for Medical Imaging, National Institute of Radiological Sciences, Chiba, Japan.

出版信息

J Nucl Med. 2000 Feb;41(2):337-44.

Abstract

UNLABELLED

111In and 90Y, dissociated from 111In-labeled-monoclonal antibody (MAb) and 90Y-labeled MAb, may cause deterioration of the image quality in radioimmunodetection (RID) and undesirable irradiation of nontargeted tissue in radioimmunotherapy (RIT), respectively. The aim of this study was to investigate any improvement in RID and RIT with 111In-MAb and 90Y-MAb by pre- and postadministration of calcium disodium ethylenetriaminetetraacetic acid (CaNa2EDTA).

METHODS

Murine MAb F33-104 against carcinoembryonic antigen (CEA) was labeled with 111In or 90Y by the diethylenetriamine pentaacetic (DTPA)-anhydride method. The influence of CaNa2EDTA on loss of radioactivity from 111In-MAb or 90Y-MAb in serum was investigated in vitro. The effects of CaNa2EDTA, administered before and after 111In-MAb or 90Y-MAb, on the biodistribution of radioactive isotopes in nude mice bearing human colon adenocarcinoma LS 180 tumor expressing CEA, or human pulmonary carcinoma PC 9 tumor expressing no CEA, were then examined. As a control, 0.9% NaCl was used in both the in vitro and in vivo studies.

RESULTS

CaNa2EDTA did not cause any decrease in levels of radioactivity of radiolabeled MAbs. Pre- and post-treatment with CaNa2EDTA reduced radioctivity in both specific and nonspecific tumors at 72 h after 111In-MAb injection resulting in an increase of the specific tumor-to-nonspecific tumor radioactivity ratio. The levels of hepatic and renal radioactivity were also subsequently decreased by CaNa2EDTA. On the other hand, CaNa2EDTA pre- and post-treatment reduced levels of bony, hepatic, and renal radioactivity at 24, 72, and 72 h, respectively, after 90Y-MAb injection, although it had no effect on tumor radioactivity.

CONCLUSION

Pre- and post-treatment with CaNa2EDTA would be of great use in humans who undergo RID or RIT with 111In-MAb and 90Y-MAb accompanied by disassociation of the labeled radionuclides.

摘要

未标记

从铟 - 111标记的单克隆抗体(MAb)和钇 - 90标记的MAb中解离出来的铟 - 111和钇 - 90,可能分别导致放射免疫检测(RID)中图像质量下降以及放射免疫治疗(RIT)中非靶向组织受到不必要的辐射。本研究的目的是通过预先和事后给予乙二胺四乙酸二钠钙(CaNa2EDTA),研究使用铟 - 111 - MAb和钇 - 90 - MAb进行RID和RIT时是否有任何改善。

方法

采用二乙三胺五乙酸(DTPA) - 酸酐法用铟 - 111或钇 - 90标记抗癌胚抗原(CEA)的鼠源MAb F33 - 104。体外研究了CaNa2EDTA对血清中铟 - 111 - MAb或钇 - 90 - MAb放射性损失的影响。然后检查了在注射铟 - 111 - MAb或钇 - 90 - MAb之前和之后给予CaNa2EDTA对携带表达CEA的人结肠腺癌LS 180肿瘤或不表达CEA的人肺癌PC 9肿瘤的裸鼠体内放射性同位素生物分布的影响。作为对照,在体外和体内研究中均使用0.9%氯化钠。

结果

CaNa2EDTA未导致放射性标记的MAb放射性水平有任何降低。在注射铟 - 111 - MAb后72小时,CaNa2EDTA的预处理和后处理均降低了特异性和非特异性肿瘤中的放射性,导致特异性肿瘤与非特异性肿瘤放射性比值增加。随后CaNa2EDTA也降低了肝脏和肾脏的放射性水平。另一方面,CaNa2EDTA的预处理和后处理分别在注射钇 - 90 - MAb后24、72和72小时降低了骨骼、肝脏和肾脏的放射性水平,尽管它对肿瘤放射性没有影响。

结论

对于接受铟 - 111 - MAb和钇 - 90 - MAb进行RID或RIT且伴有标记放射性核素解离的患者,CaNa2EDTA的预处理和后处理将非常有用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验